{"altmetric_id":2653228,"counts":{"readers":{"mendeley":42,"citeulike":0,"connotea":0},"total":{"posts_count":12},"f1000":{"unique_users_count":1,"unique_users":["F1000Prime"],"posts_count":1},"twitter":{"unique_users_count":9,"unique_users":["hypoxiapapers","ParvathaneniNK","TrueDiagnostics","SimplyMarketed","TriciaMoate","NatRevClinOncol","SarcomaOncology","Mykalt45","Wazzupdoc2"],"posts_count":9},"wikipedia":{"unique_users_count":2,"unique_users":["en:18438985","en:15025638"],"posts_count":2}},"selected_quotes":["Hypoxia-activated prodrug TH-302 and doxorubicin shows benefit in advanced soft tissue sarcoma","Phase II Study of the Safety and Antitumor Acti... [J Clin Oncol. 2014] - PubMed - NCBI Sarcoma USA study with TH-302","People may have seen this already, but here is PhII data for $THLD in STS. Don't know SoC, so can't comment +\/-.","Phase II study of TH-302 in Combination w\/ Doxorubicin in Patients w\/ Advanced Soft Tissue Sarcoma #cancerresearch"],"citation":{"abstract":"TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is preferentially activated in hypoxic conditions. This phase II study investigated TH-302 in combination with doxorubicin, followed by single-agent TH-302 maintenance therapy in patients with first-line advanced soft tissue sarcoma (STS) to assess progression-free survival (PFS), response rate, overall survival, safety, and tolerability.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e93cf058f610005a18","authors":["Sant P Chawla","Lee D Cranmer","Brian A Van Tine","Damon R Reed","Scott H Okuno","James E Butrynski","Douglas R Adkins","Andrew E Hendifar","Stew Kroll","Kristen N Ganjoo"],"doi":"10.1200\/jco.2013.54.3660","first_seen_on":"2014-09-04T21:07:45+00:00","funders":["niehs","nci"],"issns":["1527-7755"],"journal":"Journal of Clinical Oncology","last_mentioned_on":1444143307,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25185097?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter","http:\/\/jco.ascopubs.org\/content\/early\/2014\/09\/02\/JCO.2013.54.3660.abstract","http:\/\/jco.ascopubs.org\/content\/early\/2014\/09\/02\/JCO.2013.54.3660.long","http:\/\/dx.doi.org\/10.1200\/JCO.2013.54.3660","http:\/\/jco.ascopubs.org\/content\/32\/29\/3299.short?rss=1","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25185097","http:\/\/jco.ascopubs.org\/content\/early\/2014\/09\/02\/JCO.2013.54.3660"],"pmid":"25185097","pubdate":"2014-09-02T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms"],"title":"Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/phase-ii-study-safety-antitumor-activity-hypoxiaactivated-prodrug-th302-combination-doxorubicin-pati"},"altmetric_score":{"score":10.35,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":10.35},"context_for_score":{"all":{"total_number_of_other_articles":6302292,"mean":5.9475895502137,"rank":548701,"this_scored_higher_than_pct":91,"this_scored_higher_than":5750757,"rank_type":"exact","sample_size":6302292,"percentile":91},"similar_age_3m":{"total_number_of_other_articles":143335,"mean":8.4679380607533,"rank":18002,"this_scored_higher_than_pct":87,"this_scored_higher_than":125270,"rank_type":"exact","sample_size":143335,"percentile":87},"this_journal":{"total_number_of_other_articles":6667,"mean":12.188544854485,"rank":1681,"this_scored_higher_than_pct":74,"this_scored_higher_than":4979,"rank_type":"exact","sample_size":6667,"percentile":74},"similar_age_this_journal_3m":{"total_number_of_other_articles":150,"mean":19.856362416107,"rank":67,"this_scored_higher_than_pct":55,"this_scored_higher_than":83,"rank_type":"exact","sample_size":150,"percentile":55}}},"demographics":{"poster_types":{"member_of_the_public":7,"researcher":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":7,"Science communicators (journalists, bloggers, editors)":1,"Scientists":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":13,"Student  > Ph. D. Student":13,"Student  > Postgraduate":3,"Other":6,"Student  > Master":3,"Student  > Bachelor":2},"by_discipline":{"Engineering":2,"Medicine and Dentistry":19,"Chemistry":5,"Physics and Astronomy":1,"Psychology":1,"Agricultural and Biological Sciences":6,"Biochemistry, Genetics and Molecular Biology":4,"Unspecified":2,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"twitter":{"US":3,"GB":2},"mendeley":{"US":2,"JP":2,"IT":1}}},"posts":{"wikipedia":[{"title":"Evofosfamide","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=631677293#altmetric_citation_4","license":"public","citation_ids":[2653228],"posted_on":"2014-10-29T23:03:07+00:00","summary":"Evofosfamide (INN, USAN; formerly known as TH-302) is an investigational hypoxia-activated prodrug that is in clinical development for cancer treatment.","page_url":"http:\/\/en.wikipedia.org\/?curid=18438985","wiki_lang":"en","author":{"name":"LamasUI","url":"http:\/\/en.wikipedia.org\/wiki\/User:LamasUI"}},{"title":"Epithelioid sarcoma","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=684420975#altmetric_citation_058a7539-a58d-42b5-99fb-85ec0f21acd1","license":"public","citation_ids":[2653228],"posted_on":"2015-10-06T14:55:07+00:00","summary":"Epithelioid sarcoma is a rare soft tissue sarcoma arising from mesenchymal tissue and characterized by epithelioid-like features.","page_url":"http:\/\/en.wikipedia.org\/?curid=15025638","wiki_lang":"en","author":{"name":"Chris Capoccia","url":"http:\/\/en.wikipedia.org\/wiki\/User:Chris Capoccia"}}],"twitter":[{"url":"https:\/\/twitter.com\/hypoxiapapers\/status\/507489701951836160","license":"datasift","citation_ids":[2653228],"posted_on":"2014-09-04T11:25:48+00:00","author":{"name":"Hypoxia Adaptation","image":"https:\/\/pbs.twimg.com\/profile_images\/491585034201989120\/716F2y0d_normal.png","description":"A feed for hypoxia related papers published in NCBI, ArXiv, bioArxiv, and PeerJ","id_on_source":"hypoxiapapers","tweeter_id":"2669362848","geo":{"lt":null,"ln":null},"followers":409},"tweet_id":"507489701951836160"},{"url":"https:\/\/twitter.com\/ParvathaneniNK\/status\/507128265115721728","license":"datasift","rt":["NatRevClinOncol"],"citation_ids":[2653228],"posted_on":"2014-09-03T11:29:35+00:00","author":{"name":"Nanda Parvathaneni","image":"https:\/\/pbs.twimg.com\/profile_images\/730824733772648449\/Pjd2LcYO_normal.jpg","id_on_source":"ParvathaneniNK","tweeter_id":"1660690400","geo":{"lt":null,"ln":null},"followers":39},"tweet_id":"507128265115721728"},{"url":"https:\/\/twitter.com\/TrueDiagnostics\/status\/518177154056876032","license":"datasift","citation_ids":[2653228],"posted_on":"2014-10-03T23:13:55+00:00","author":{"name":"Jerry Lee","url":"http:\/\/www.truediag.com","image":"https:\/\/pbs.twimg.com\/profile_images\/567483990097936384\/6uKJglvi_normal.jpeg","description":"We specialize in providing quick & simple quantitative test systems designed for point-of-care monitoring. Test results in minutes not days..","id_on_source":"TrueDiagnostics","tweeter_id":"317232537","geo":{"lt":32.71533,"ln":-117.15726,"country":"US"},"followers":374},"tweet_id":"518177154056876032"},{"url":"https:\/\/twitter.com\/SimplyMarketed\/status\/521601446656364544","license":"datasift","rt":["TriciaMoate"],"citation_ids":[2653228],"posted_on":"2014-10-13T10:00:50+00:00","author":{"name":"Simply Marketed","url":"http:\/\/simplymarketed.com","image":"http:\/\/pbs.twimg.com\/profile_images\/2289751932\/21fqecmue0xhjadgidap_normal.jpeg","description":"We are a Boston-based marketing company that provides SEO, video editing, marketing and social media services to restaurants and small businesses.","id_on_source":"SimplyMarketed","tweeter_id":"581060325","geo":{"lt":"42.3604823","ln":"-71.0595678","country":"US"},"followers":1056},"tweet_id":"521601446656364544"},{"url":"https:\/\/twitter.com\/TriciaMoate\/status\/521595646109696000","license":"datasift","citation_ids":[2653228],"posted_on":"2014-10-13T09:37:47+00:00","author":{"name":"Tricia Moate","image":"https:\/\/pbs.twimg.com\/profile_images\/492377072371638272\/Qw2-EmJc_normal.jpeg","description":"Wife, mother, member of sarcoma support group. Dalmatian lover. Always been a dolly daydreamer.","id_on_source":"TriciaMoate","tweeter_id":"2669795143","geo":{"lt":"50.75","ln":"-2.333333","country":"GB"},"followers":39},"tweet_id":"521595646109696000"},{"url":"https:\/\/twitter.com\/NatRevClinOncol\/status\/507119150956052482","license":"datasift","citation_ids":[2653228],"posted_on":"2014-09-03T10:53:22+00:00","author":{"name":"NatureRevClinOncol","url":"http:\/\/www.nature.com\/nrclinonc\/index.html","image":"https:\/\/pbs.twimg.com\/profile_images\/1587954262\/nrclinonc_Twitter_logo_normal.jpg","description":"The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.","id_on_source":"NatRevClinOncol","tweeter_id":"347276297","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":10481},"tweet_id":"507119150956052482"},{"url":"https:\/\/twitter.com\/SarcomaOncology\/status\/516749322839281664","license":"datasift","citation_ids":[2653228],"posted_on":"2014-09-30T00:40:13+00:00","author":{"name":"Sarcoma Oncology","url":"http:\/\/sarcomaoncology.com\/","image":"https:\/\/pbs.twimg.com\/profile_images\/515538054304391170\/W2jA7O5s_normal.jpeg","description":"A premier oncology institute specializing in the advanced treatment of sarcomas & leading the way in groundbreaking clinical trials. #sarcomaoncology","id_on_source":"SarcomaOncology","tweeter_id":"2777082512","geo":{"lt":34.01945,"ln":-118.49119,"country":"US"},"followers":185},"tweet_id":"516749322839281664"},{"url":"https:\/\/twitter.com\/Mykalt45\/status\/509360253750611968","license":"datasift","citation_ids":[2653228],"posted_on":"2014-09-09T15:18:42+00:00","author":{"name":"Michael Torres, PhD","url":"https:\/\/t.co\/hLv1oICDyS","image":"http:\/\/pbs.twimg.com\/profile_images\/727832195415445505\/-KHYISIy_normal.jpg","description":"PhD in Cancer Biology\/Cystic Fibrosis researcher now, an avid Mac user, amateur music creator, art and fitness enthusiast. Trader. Co-founder.","id_on_source":"Mykalt45","tweeter_id":"289311242","followers":2516},"tweet_id":"509360253750611968"},{"url":"https:\/\/twitter.com\/Wazzupdoc2\/status\/593380231555067905","license":"datasift","citation_ids":[2653228],"posted_on":"2015-04-29T11:44:06+00:00","author":{"name":"Wazzupdoc","image":"https:\/\/pbs.twimg.com\/profile_images\/529611869036625920\/keXLrWoP_normal.png","id_on_source":"Wazzupdoc2","tweeter_id":"2889767143","followers":8},"tweet_id":"593380231555067905"}],"f1000":[{"title":"Recommended in F1000 Prime","url":"https:\/\/f1000.com\/prime\/718556209","license":"public","citation_ids":[2653228],"posted_on":"2014-09-23T00:00:00+00:00","f1000_classes":["new_finding"],"f1000_score":"2"}]}}